MX2016011938A - Composicion farmaceutica liquida. - Google Patents

Composicion farmaceutica liquida.

Info

Publication number
MX2016011938A
MX2016011938A MX2016011938A MX2016011938A MX2016011938A MX 2016011938 A MX2016011938 A MX 2016011938A MX 2016011938 A MX2016011938 A MX 2016011938A MX 2016011938 A MX2016011938 A MX 2016011938A MX 2016011938 A MX2016011938 A MX 2016011938A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
provides
magnesium oxide
present
Prior art date
Application number
MX2016011938A
Other languages
English (en)
Other versions
MX366499B (es
Inventor
Gil Nam Bong
Original Assignee
Pharmbio Korea Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51742358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016011938(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmbio Korea Co Ltd filed Critical Pharmbio Korea Co Ltd
Publication of MX2016011938A publication Critical patent/MX2016011938A/es
Publication of MX366499B publication Critical patent/MX366499B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una composición farmacéutica líquida fisicoquímicamente estable, la cual comprende picosulfato de sodio, óxido de magnesio, ácido cítrico y ácido málico.
MX2016011938A 2014-03-19 2014-06-23 Composicion farmaceutica liquida. MX366499B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140032242A KR101420315B1 (ko) 2014-03-19 2014-03-19 약학적 액제 조성물
PCT/KR2014/005512 WO2015141897A1 (ko) 2014-03-19 2014-06-23 약학적 액제 조성물

Publications (2)

Publication Number Publication Date
MX2016011938A true MX2016011938A (es) 2017-05-30
MX366499B MX366499B (es) 2019-07-11

Family

ID=51742358

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011938A MX366499B (es) 2014-03-19 2014-06-23 Composicion farmaceutica liquida.

Country Status (11)

Country Link
US (4) US9827231B2 (es)
EP (1) EP3120835B1 (es)
JP (1) JP6347891B2 (es)
KR (1) KR101420315B1 (es)
CN (1) CN106456534B (es)
AU (1) AU2014386903B2 (es)
CA (1) CA2942878C (es)
ES (1) ES2907324T3 (es)
MX (1) MX366499B (es)
RU (1) RU2668882C2 (es)
WO (1) WO2015141897A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101420315B1 (ko) 2014-03-19 2014-07-17 남봉길 약학적 액제 조성물
EP3337513A1 (en) * 2015-08-17 2018-06-27 Ferring B.V. Liquid formulations containing picosulfate and magnesium citrate
CN108601842A (zh) * 2016-01-28 2018-09-28 西梯茜生命工学股份有限公司 泻药组合物
US20180015078A1 (en) * 2016-07-08 2018-01-18 Ferring B.V. Stabilized liquid formulations containing picosulfate
KR101839773B1 (ko) 2016-12-07 2018-03-19 (주)대명산업 해초제거제
KR101960268B1 (ko) * 2017-01-04 2019-03-21 어업회사법인 블루오션(주) 녹조류 제거제
US11471447B2 (en) 2019-06-20 2022-10-18 Hetero Labs Limited Stable pharmaceutical product and vessel comprising sodium picosulfate, magnesium oxide and citric acid

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5697248A (en) 1979-12-28 1981-08-05 Tanaka Shiro Conjugated compound of calcium citrate and calcium malate and its preparation
US5010069A (en) 1989-05-15 1991-04-23 Marion Laboratories, Inc. Stable liquid form of 5-aminosalicylic acid
FR2647347A1 (fr) 1989-05-24 1990-11-30 Lucien Laboratoires Agents et complexes de l'ion mg2+ facilitant l'absorption du magnesium dans un organisme humain ou animal, et compositions pharmaceutiques ou dietetiques utilisables pour l'administration de magnesium dans un organisme humain ou animal
JP2557111B2 (ja) 1989-11-27 1996-11-27 フジックス 株式会社 高濃度のマグネシウム溶液の製造方法及びそれによって得られたマグネシウム溶液並びにその用途
DE69109289T2 (de) 1990-06-14 1995-10-26 Procter & Gamble Calciumcitrat/malat-gemisch.
AU9046591A (en) 1990-10-31 1992-05-26 Procter & Gamble Company, The Calcium fortified sauces
JP2930737B2 (ja) 1990-12-27 1999-08-03 雪印乳業株式会社 カルシウム強化食品およびその製造方法
US5498425A (en) * 1995-03-17 1996-03-12 Block Drug Company, Inc. Phosphosoda buffered saline laxative
JPH10327805A (ja) 1997-06-02 1998-12-15 Yasuma Kk マグネシウム含有食品組成物
JPH11299454A (ja) 1998-04-27 1999-11-02 Sankyo Foods Kk ドロマイトの可溶化方法
JP5070669B2 (ja) 2000-03-10 2012-11-14 大正製薬株式会社 防腐性を向上した経口用ゲル製剤
JP4245821B2 (ja) 2000-04-28 2009-04-02 協和発酵バイオ株式会社 カルシウムおよびマグネシウム溶液及びそれを含有する飲食品並びにそれらの製造方法
GB0224909D0 (en) * 2002-10-25 2002-12-04 Norgine Europe Bv Colon cleansing compositions
GB0307918D0 (en) * 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
US7382110B2 (en) 2004-04-23 2008-06-03 Sony Corporation Method of charging secondary battery, method of calculating remaining capacity rate of secondary battery, and battery pack
IN2006CH01605A (es) 2006-09-05 2008-11-28 Global Calcium Pvt Ltd
CN101820859B (zh) 2007-10-12 2013-05-01 辉凌国际制药（瑞士）有限公司 制备包含枸橼酸、氧化镁、碳酸氢钾和匹可硫酸钠的药物产品的方法,包含通过该方法获得的细粒的药物组合物以及中间体
EP2515858A1 (en) * 2009-12-25 2012-10-31 Mahmut Bilgic Pharmaceutical composition with high purity
WO2011142731A2 (en) * 2010-05-14 2011-11-17 Mahmut Bilgic Formulations comprising a third generation cephalosporin and clavulanic acid
WO2012102799A2 (en) * 2011-01-28 2012-08-02 Shaver William A Method, composition and package for bowel cleansing
AU2012284200B2 (en) 2011-07-15 2016-09-22 Ferring B.V. Method for timing a colonoscopy wherein a picosulate composition is administered
WO2013086382A1 (en) * 2011-12-07 2013-06-13 Msm Innovations, Inc. Method for bowel preparation
KR101155099B1 (ko) 2012-03-29 2012-06-11 남봉길 장 세척용 조성물의 제조 방법 및 이에 의해 제조된 장 세척용 조성물
PT2877163T (pt) 2012-07-27 2019-05-24 Redhill Biopharma Ltd Formulações e métodos de fabrico de formulações para utilização na evacuação colónica
KR20150046310A (ko) * 2012-08-29 2015-04-29 샐릭스 파마슈티컬스 인코포레이티드 완화제 조성물 및 변비 및 관련 위장관 질병 및 증상 치료를 위한 방법
KR101517520B1 (ko) * 2013-08-05 2015-05-04 이희엽 피코황산나트륨 함유 장 세척용 조성물의 제조방법
IN2013MU02911A (es) 2013-09-10 2015-07-03 Cadila Healthcare Ltd
KR101420315B1 (ko) 2014-03-19 2014-07-17 남봉길 약학적 액제 조성물
EP3337513A1 (en) 2015-08-17 2018-06-27 Ferring B.V. Liquid formulations containing picosulfate and magnesium citrate
US20180015078A1 (en) 2016-07-08 2018-01-18 Ferring B.V. Stabilized liquid formulations containing picosulfate

Also Published As

Publication number Publication date
RU2016138577A (ru) 2018-04-20
US20200345708A1 (en) 2020-11-05
CA2942878C (en) 2021-08-24
US10624879B2 (en) 2020-04-21
WO2015141897A1 (ko) 2015-09-24
JP2017508815A (ja) 2017-03-30
US20180235947A1 (en) 2018-08-23
EP3120835A4 (en) 2017-10-18
US11191753B2 (en) 2021-12-07
JP6347891B2 (ja) 2018-06-27
AU2014386903A1 (en) 2016-11-03
KR101420315B1 (ko) 2014-07-17
MX366499B (es) 2019-07-11
EP3120835A1 (en) 2017-01-25
US20220193052A1 (en) 2022-06-23
CN106456534A (zh) 2017-02-22
CN106456534B (zh) 2019-05-14
EP3120835B1 (en) 2021-12-08
AU2014386903B2 (en) 2020-01-30
US20160324837A1 (en) 2016-11-10
RU2668882C2 (ru) 2018-10-04
US9827231B2 (en) 2017-11-28
CA2942878A1 (en) 2015-09-24
ES2907324T3 (es) 2022-04-22

Similar Documents

Publication Publication Date Title
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
MX366499B (es) Composicion farmaceutica liquida.
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
EP3679945A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITION
PH12017502028A1 (en) Vortioxetine pyroglutamate
MX2017009653A (es) Composicion de bebida en polvo.
IN2014MU01248A (es)
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
EP3135293A4 (en) Agent for preventing or ameliorating diabetes
SG10201900598TA (en) Factor viii formulation
IL268678B (en) Formulas of 1-amino-1-cyclopropane-carboxylic acid
PL3223611T3 (pl) Dwuskładnikowa kompozycja dezynfekująca zawierająca kwas nadoctowy i środek chelatujący
IN2014CH00840A (es)
EP3402470A4 (en) STABLE PHARMACEUTICAL COMPOSITION
AU2016361427A8 (en) Platinum anticancer agents
PL3645016T3 (pl) Połączenie zawierające tlen i kwas hialuronowy do stosowania miejscowego-dopochwowego
MY183068A (en) Pharmaceutical formulation comprising antibody
IL252683B (en) Pyridyl-cycloalkyl-substituted carboxylic acids, preparations containing them and their medical uses
EP3299025A4 (en) COMPOSITION WITH QUISQUALIS INDICA
EP3337324A4 (en) DISINFECTION COMPOSITION FOR RESIDUES
MX2016011401A (es) Composiciones farmaceuticas que comprenden levocetirizina.
MY188169A (en) Pharmaceutical compositions and use thereof
IL266659B (en) Fgfr4 inhibitor, pharmaceutical composition comprising it and use thereof
MA40027A (fr) Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique
EP3154524A4 (en) Extended-release drug delivery compositions

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: FERRING INTERNATIONAL CENTER SA

FG Grant or registration